Grifols (NASDAQ:GRFS) Shares Gap Down – Time to Sell?

Shares of Grifols, S.A. (NASDAQ:GRFS) gapped down prior to trading on Monday . The stock had previously closed at $8.73, but opened at $8.39. Grifols shares last traded at $8.49, with a volume of 91,998 shares traded.

Grifols Price Performance

The business’s 50 day moving average is $8.80 and its two-hundred day moving average is $7.76. The firm has a market capitalization of $5.64 billion, a PE ratio of 8.12 and a beta of 0.50. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.68 and a quick ratio of 0.80.

Grifols (NASDAQ:GRFS) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.21). The company had revenue of $1.96 billion for the quarter. As a group, research analysts anticipate that Grifols, S.A. will post 0.79 EPS for the current year.

Hedge Funds Weigh In On Grifols

Several hedge funds and other institutional investors have recently modified their holdings of GRFS. GAMMA Investing LLC grew its stake in shares of Grifols by 49.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,135 shares during the last quarter. Signaturefd LLC boosted its stake in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 2,153 shares during the last quarter. Cohen Investment Advisors LLC purchased a new stake in Grifols in the 1st quarter worth approximately $80,000. AQR Capital Management LLC bought a new position in shares of Grifols in the second quarter worth about $89,000. Finally, Creative Planning grew its stake in Grifols by 26.4% during the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock valued at $154,000 after acquiring an additional 3,614 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.